Atrial Fibrillation in Long Term Care

Journal of the American Medical Directors Association

Volumn 13, Issue 8, 2012, Pages 688-691

  Rich, Michael W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aged; Anticoagulation; Atrial fibrillation; Long term care; Nursing homes

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; APIXABAN; DABIGATRAN; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; MAGNESIUM; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RIVAROXABAN; SOTALOL; TROPONIN; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CELL COUNT; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAGNESIUM BLOOD LEVEL; NURSING HOME PATIENT; PATIENT MONITORING; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; RISK REDUCTION; SINUS RHYTHM; SYMPTOM; THROMBOSIS PREVENTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84866770683     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2012.07.009     Document Type: Review

References (35)

1. Gurwitz J.H., Monette J., Rochon P.A., et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997, 157:978-984.
2. Latif A.K.A., Peng X., Messinger-Rapport B.J. Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation. J Am Med Dir Assoc 2005, 6:128-131.
3. McCormick D., Gurwitz J.H., Goldberg R.J., et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001, 161:2458-2463.
4. Reardon G., Nelson W., Patel A.A., et al. Prevalence of atrial fibrillation in U.S. nursing homes: Results from the National Nursing Home Survey, 1985-2004. JAMDA 2012, 13:529-534.
5. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
6. Lip G.Y., Halperin J.L. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010, 123:484-488.
7. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991, 22:983-988.
8. Avgil-Tsadok M., Jackevicius C.A., Rahme E., et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012, 307:1952-1958.
9. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2011, 57:e101-e198.
10. De Denus S., Sanoski C.A., Carlsson J., et al. Rate vs. rhythm control in patients with atrial fibrillation: A meta-analysis. Arch Intern Med 2005, 165:258-262.
11. Caldeira D., David C., Sampaio C. Rate vs rhythm control in patients with atrial fibrillation and heart failure: A systematic review and meta-analysis of randomised controlled trials. Eur J Intern Med 2011, 22:448-455.
12. Lane D.A., Lip G.Y. Quality of life in older people with atrial fibrillation. J Intervent Cardiac Electrophys 2009, 25:37-42.
13. Van Gelder I.C., Groenveld H.F., Crijns H.J., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010, 362:1363-1373.
14. Saksena S., Slee A., Waldo A.L., et al. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol 2011, 58:1975-1985.
15. Hohnloser S.H., Crijns H.J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668-678.
16. Connolly S.J., Camm A.J., Halperin J.L., et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011, 365:2268-2276.
17. Crandall M.A., Bradley D.J., Packer D.L., Asirvatham S.J. Contemporary management of atrial fibrillation: Update on anticoagulation and invasive management strategies. Mayo Clin Proc 2009, 84:643-662.
18. Wazni O., Wilkoff B., Saliba W. Catheter ablation for atrial fibrillation. N Engl J Med 2011, 365:2296-2304.
19. Lee A.M., Melby S.J., Damiano R.J. The surgical treatment of atrial fibrillation. Surg Clin North Am 2009, 89:1001-1020.
20. Yamada T., Kay G.N. Catheter ablation of atrial fibrillation in the elderly. Pacing Clin Electrophys 2009, 32:1085-1091.
21. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007, 370:493-503.
22. White H.D., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007, 167:239-245.
23. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
24. Hankey G.J., Eikelboom J.W. Dabigatran etexilate: A new oral thrombin inhibitor. Circulation 2011, 123:1436-1450.
25. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
26. Harper P., Young L., Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012, 366:864-866.
27. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
28. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
29. Monette J., Gurwitz J.H., Rochon P.A., Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: Results of a survey of long-term care practitioners. J Am Geriatr Soc 1997, 45:1060-1065.
30. Garwood C.L., Corbett T.L. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother 2008, 42:523-532.
31. Lau E., Bungard T.J., Tsuyuki R.T. Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. J Am Geriatr Soc 2004, 52:428-433.
32. Singh P., Arrevad P.S., Peterson G.M., Bereznicki L.R. Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities. J Clin Pharm Ther 2011, 36:166-171.
33. Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
34. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012.
35. Gurwitz J.H., Field T.S., Radford M.J., et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007, 120:539-544.